Allianz Asset Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $573K | Buy |
8,696
+1,455
| +20% | +$92.5K | ﹤0.01% | 1824 |
|
|
2025
Q4 | $460K | Buy |
7,241
+2,700
| +59% | +$168K | ﹤0.01% | 1847 |
|
|
2025
Q3 | $250K | Buy |
+4,541
| New | +$187K | ﹤0.01% | 1936 |
|
|
2025
Q1 | – | Sell |
-9,600
| Closed | -$452K | – | 2238 |
|
|
2024
Q4 | $452K | Buy |
9,600
+4,300
| +81% | +$223K | ﹤0.01% | 1894 |
|
|
2024
Q3 | $280K | Sell |
5,300
-7,600
| -59% | -$424K | ﹤0.01% | 2005 |
|
|
2024
Q2 | $699K | Sell |
12,900
-4,400
| -25% | -$266K | ﹤0.01% | 1719 |
|
|
2024
Q1 | $1.21M | Buy |
17,300
+11,200
| +184% | +$866K | ﹤0.01% | 1355 |
|
|
2023
Q4 | $509K | Sell |
6,100
-9,500
| -61% | -$344K | ﹤0.01% | 1851 |
|
|
2023
Q3 | $460K | Hold |
15,600
| – | – | ﹤0.01% | 1951 |
|
|
2023
Q2 | $509K | Buy |
15,600
+9,500
| +156% | +$351K | ﹤0.01% | 1737 |
|
|
2023
Q1 | $215K | Sell |
6,100
-11,000
| -64% | -$449K | ﹤0.01% | 2035 |
|
|
2022
Q4 | $784K | Sell |
17,100
-6,181
| -27% | -$266K | ﹤0.01% | 1597 |
|
|
2022
Q3 | $1.13M | Sell |
23,281
-135,841
| -85% | -$6.54M | ﹤0.01% | 1389 |
|
|
2022
Q2 | $6.25M | Buy |
159,122
+92,782
| +140% | +$3.74M | 0.01% | 1028 |
|
|
2022
Q1 | $2.44M | Sell |
66,340
-76,797
| -54% | -$2.73M | ﹤0.01% | 1522 |
|
|
2021
Q4 | $6.53M | Buy |
+143,137
| New | +$5.52M | ﹤0.01% | 1138 |
|
|
2020
Q4 | – | Sell |
-24,858
| Closed | -$538K | – | 1868 |
|
|
2020
Q3 | $538K | Buy |
+24,858
| New | +$581K | ﹤0.01% | 1593 |
|
|
2018
Q3 | – | Sell |
-114,691
| Closed | -$952K | – | 2619 |
|
|
2018
Q2 | $952K | Sell |
114,691
-671
| -0.6% | -$5.58K | ﹤0.01% | 2248 |
|
|
2018
Q1 | $831K | Buy |
115,362
+3,305
| +3% | +$28.3K | ﹤0.01% | 2260 |
|
|
2017
Q4 | $913K | Sell |
112,057
-1,406
| -1% | -$16K | ﹤0.01% | 2263 |
|
|
2017
Q3 | $1.65M | Buy |
113,463
+8,925
| +9% | +$122K | ﹤0.01% | 2078 |
|
|
2017
Q2 | $1.26M | Buy |
104,538
+20,062
| +24% | +$279K | ﹤0.01% | 2134 |
|
|
2017
Q1 | $1.09M | Buy |
+84,476
| New | +$987K | ﹤0.01% | 2212 |
|
|
2014
Q4 | – | Sell |
-69,309
| Closed | -$244K | – | 2355 |
|
|
2014
Q3 | $244K | Sell |
69,309
-198,151
| -74% | -$832K | ﹤0.01% | 2110 |
|
|
2014
Q2 | $1.28M | Sell |
267,460
-43,393
| -14% | -$265K | ﹤0.01% | 1325 |
|
|
2014
Q1 | $2.95M | Buy |
310,853
+15,770
| +5% | +$143K | ﹤0.01% | 1090 |
|
|
2013
Q4 | $1.92M | Hold |
295,083
| – | – | ﹤0.01% | 1223 |
|
|
2013
Q3 | $2.23M | Hold |
295,083
| – | – | ﹤0.01% | 1162 |
|
|
2013
Q2 | $3.41M | Buy |
+295,083
| New | +$2.32M | ﹤0.01% | 1024 |
|
Other funds holding CYTK
VPM
VCM
ACA
Allianz Asset Management's CYTK Position: Q1 2026 in Review
Allianz Asset Management increased its Cytokinetics (CYTK) stake by 20% in Q1 2026, buying an estimated $92.5K and bringing the position to 8,696 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #1824.
Allianz Asset Management first reported a position in CYTK in Q2 2013 and has held it in 29 quarters since. The position peaked at $6.53M in Q4 2021. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Allianz Asset Management held 8,696 shares of Cytokinetics worth $573K as of Q1 2026.
- Allianz Asset Management bought 1,455 Cytokinetics shares in Q1 2026, an estimated $92.5K.
- Cytokinetics made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1824 holding.
- Allianz Asset Management first reported a position in Cytokinetics in Q2 2013 and has held it in 29 quarters since.
- Allianz Asset Management's Cytokinetics position peaked at $6.53M in Q4 2021.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.